Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04087681 · ClinicalTrials.gov registry record

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)

A clinical trial of E.Coli Infections, sponsored by MJM Bonten.

Completed
Registry status
4,479
Enrollment target
8
Study locations

NCT04087681 is a study of E.Coli Infections that has completed, run by MJM Bonten. The registered enrollment target is 4,479 participants. The trial reports 8 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04087681, a study of E.Coli Infections, has completed, sponsored by MJM Bonten.

COMPLETED
Registry status
4,479 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to collect information from study participants who develop an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC) during a period of 12 months. This information will be used to support the development of a new vaccine to prevent ExPEC infections.

Conditions Studied

Study Locations (8)

Other

  • Duke Clinical Research Institute - Greater Sudbury
  • Chu Limoges - Cic - Limoges
  • UKK Uniclinic Cologne - Cologne
  • University of Verona - Verona
  • - Andalusian Public Foundation for Health Research Management in Seville (FISEVI) - Seville
  • University of Oxford - Oxford

North Carolina

  • Duke Clinical Research Institute - Durham

Chiyoda-ku

  • Janssen Pharmaceutical K.K. - Tokyo

Trial Details

FieldValue
Enrollment Target 4,479 participants
Start Date 2019-09-28
Est. Completion 2021-06-21

Sponsor

MJM Bonten

1 total trials

What the Registry Record Tells You About NCT04087681

The ClinicalTrials.gov registry entry for NCT04087681 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,479 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MJM Bonten, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with E.Coli Infections appearing as the primary indexed condition, and to 0 interventions.

NCT04087681 reports 8 study locations spanning 3 distinct geographic areas - top geographies include Other, North Carolina, Chiyoda-ku.

Frequently Asked Questions

What is clinical trial NCT04087681 about?

NCT04087681 is a clinical study titled "Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)". The purpose of this study is to collect information from study participants who develop an invasive disease caused by Extraintestinal pathogenic E. coli (ExPEC) during a period of 12 months. This information will be used to support the development of a new vaccine to prevent ExPEC infections.

What is the current status of trial NCT04087681?

This trial is currently completed. The enrollment target is 4,479 participants. The study started on 2019-09-28. Estimated completion is 2021-06-21.

What conditions does trial NCT04087681 study?

This clinical trial studies the following conditions: E.Coli Infections.

Who is sponsoring clinical trial NCT04087681?

This trial is sponsored by MJM Bonten, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04087681 being conducted?

This trial has 8 study locations across North Carolina, Chiyoda-ku. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for E.Coli Infections

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.